---
layout: default
title: Rocuronium
parent: Model Prediction Only (L5)
nav_order: 301
evidence_level: L5
indication_count: 10
---

# Rocuronium
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Rocuronium: From Neuromuscular Blockade in Anaesthesia to Migraine Disorder

## One-Sentence Summary

Rocuronium is a non-depolarizing neuromuscular blocker used as an anaesthetic adjunct. The TxGNN model predicts it may be effective for **migraine disorder**, but this is a model-only prediction. The data compiled for this report show **1 clinical trial** (not relevant to the indication) and **no supporting publications** for migraine, so the evidence is very weak.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in the Philippines registration data (rocuronium is generally used as a neuromuscular blocker for intubation and surgical muscle relaxation) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 |
| Philippines Market Status | Cancelled only (no currently valid registration) |
| Number of Registrations | 1 (0 valid, 1 cancelled) |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Rocuronium is known as a non-depolarizing neuromuscular blocker. It acts as a competitive antagonist at postsynaptic nicotinic acetylcholine receptors at the neuromuscular junction, causing temporary skeletal muscle paralysis.

No established mechanism links this action to migraine. Migraine involves CGRP signalling, trigeminovascular activation and cortical spreading depression, none of which rocuronium is known to influence. Peripheral muscle paralysis is not a plausible antimigraine mechanism.

The high TxGNN score (99.90%) is a graph-based prediction. It is probably driven by network proximity to other neuromuscular or neurological agents rather than by biological evidence. It should be treated as a hypothesis-generating signal only.

Other top-ranked predictions (migraine with brainstem aura, cauda equina syndrome, irritable bowel syndrome, sciatic neuropathy, and several rare skin disorders) also lack plausible mechanistic support. Several of them appear to inherit their scores from the parent migraine node in the knowledge graph.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT01431326](https://clinicaltrials.gov/study/NCT01431326) | N/A | Completed | 3520 | Pharmacokinetic study of understudied drugs given to children as standard of care. Rocuronium is one of many drugs studied. It was not designed to test efficacy in migraine and provides no evidence for this indication. |

---

## Literature Evidence

No publications on rocuronium for migraine disorder were found in the data compiled for this report.

For the related prediction **headache disorder** (rank 10), two publications were found. They provide only indirect evidence:

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [23812022](https://pubmed.ncbi.nlm.nih.gov/23812022/) | 2014 | Clinical study (anaesthesia/ECT setting) | The Journal of ECT | Compared succinylcholine with rocuronium-sugammadex for myalgia and headache after electroconvulsive therapy. This concerns avoiding a post-procedural adverse effect, not treating a headache disorder. |
| [24196089](https://pubmed.ncbi.nlm.nih.gov/24196089/) | 2013 | Case report | Pediatric Emergency Care | Rapid sequence intubation in a child with raised intracranial pressure. It does not address headache treatment. |

---

## Philippines Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| PNF-0429 | Rocuronium | Not specified | Not specified (registration status: cancelled) |

---

## Safety Considerations

- **Drug Interactions**: 73 interactions were recorded in the interaction database. Examples among those retrieved:
  - **Major**: paromomycin, kanamycin, neomycin (aminoglycosides, which may potentiate neuromuscular blockade).
  - **Moderate**: tetracyclines (doxycycline, tetracycline, minocycline), vancomycin, magnesium sulfate and magnesium chloride, amphotericin B, corticosteroids (hydrocortisone, dexamethasone, betamethasone, prednisone, triamcinolone), mannitol, metoclopramide, topical neomycin.
  - **Minor**: ranitidine.

Please refer to the package insert for warnings and contraindications.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The prediction rests only on a graph-based model score. There is no plausible mechanism linking neuromuscular blockade to migraine. The only trial found is not relevant to the indication, and no supporting literature exists.
- Rocuronium is a systemic, short-acting intravenous anaesthetic agent that is unsuitable for chronic migraine management. It currently has no valid registration in the Philippines.

**To proceed, the following is needed:**
- Mechanistic evidence for any link between rocuronium (or neuromuscular blockade) and migraine pathophysiology
- Preclinical or clinical studies specifically addressing migraine or headache as a treatment target
- Confirmation of the original indication, dosage forms and current registration status in the Philippines
- Package insert safety information (warnings and contraindications) and the full mechanism of action data
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

